Studies have shown that blocking TLR2 prevents spontaneous cytokine release from RA in vitro synovial graft cultures [24], and TLR4 antagonists inhibit the spontaneous secretion of TNF-α and IL-1β from synovial tissue cultures in vivo [25]; all of this evidence implies that Jinwujiangu prescription may treat RA by acting on these signaling pathways. The gene discussed is IL1B; the disease is rheumatoid arthritis.